Financials data is unavailable for this security.
View more
Year on year Tibet Weixinkang Pharmaceutical Co Ltd had revenues fall -5.43% from 1.40bn to 1.32bn, though the company grew net income 20.94% from 176.96m to 214.02m.
| Gross margin | 53.45% |
|---|---|
| Net profit margin | 19.67% |
| Operating margin | 18.43% |
| Return on assets | 13.33% |
|---|---|
| Return on equity | 17.48% |
| Return on investment | 17.01% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Tibet Weixinkang Pharmaceutical Co Ltd fell by 249.90m. However, the company earned 241.12m from its operations for a Cash Flow Margin of 18.23%. In addition the company used 389.21m on investing activities and also paid 102.44m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 3.41 |
|---|---|
| Tangible book value per share | 3.29 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.36 |
|---|---|
| Quick ratio | 3.27 |
| Total debt/total equity | 0.0076 |
|---|---|
| Total debt/total capital | 0.0075 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 21.28% and 19.95%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 1.48% |
|---|---|
| Div growth rate (5 year) | 38.96% |
| Payout ratio (TTM) | 50.20% |
| EPS growth(5 years) | 23.15 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 4.19 |
More ▼
